Science Pool

Note: This article was developed for Bio Europe Supplement, EBR Autumn Edition 2024, Samedan Ltd 

Just – Evotec Biologics explores how, through offering enhanced productivity, cost efficiency, agility and more, continuous manufacturing processes and facilities are improving global access to biologics. 

Learn More

Note: This article was developed for Bio Europe Supplement, EBR Autumn Edition 2024, Samedan Ltd 

Discover how an optimized hit identification strategy, integrating advanced tools – including AI and machine learning – can provide the best possible chemical starting points. Explore how Evotec’s collaborative approach is key to identifying high-quality hits at lightning speed, saving on costs and time, while reducing the risk of attrition. 

Learn More

As our understanding of conformational chemistry advances, we can explore a variety of strategies beyond cyclization to restrict the number of low-energy conformations accessible to ligands. These alternative approaches offer the potential to optimize binding affinity and enhance the overall pharmacological profile of ligands, facilitating more efficient drug design and discovery.

In this comprehensive review we highlighted the essential role of conformational drivers in drug design, exploring how molecular conformation influences key drug properties with real-world examples.

Machine Learning (ML) is becoming critical for the design and development of therapeutics. Just-Evotec Biologics has created a Humanoid Antibody Library for the discovery of biopharmaceuticals that is the first step towards leveraging artificial intelligence and ML. 

In this publication we describe how we have started the validation of the library by isolating antibodies against a target of pandemic concern, SARS-CoV-2.

We successfully identified a panel of human monoclonal antibodies that are novel, diverse, and pharmacologically active. These first-generation antibodies exhibited neutralization of SARS-CoV-2 viral infectivity across multiple strains and indicated high developability potential.

These results demonstrate the applicability of our platform for effective therapeutic antibody discovery.

Learn More

Biopharmaceutical companies increasingly want to convert fed-batch manufacturing processes to continuous platforms. We teamed up with GLOBAL Regulatory Writing & Consulting for this whitepaper so that you can learn:

• How to meet regulatory expectations when switching to continuous manufacturing
• The importance of appropriate risk assessments
• How to demonstrate comparability with previously manufactured material

Learn More

With active partnerships across 3 continents with more than 40 top-tier academic partners and a diverse cohort of investors, Evotec’s BRIDGEs have become a globally leading pre-seed accelerator initiative.

Alongside operational BRIDGE-building, our team has also been reflecting conceptually on the challenges and best practices in accelerating the transition from an academic starting point in drug discovery to an investable proof of concept. 

Key thoughts are now summarized in our whitepaper mini-series: ‘From academic concept to commercial reality: How to accelerate translational drug discovery’

In three chapters we share openly our insights and views to inspire a continued dialogue between academic researchers, investors, and biotech and pharma colleagues on how to build an even more robust translational community and – together, for medicines that matter - develop new first-in-class therapies and platforms.

Download the free content!

• INTRODUCTION
• CHAPTER 1
• CHAPTER 2
• CHAPTER 3
  
  

Visit our Academic BRIDGEs website page 

Discuss your project with us:

Get in touch

Just- Evotec Biologics is pioneering a new era in biomanufacturing. Transitioning to our intensified continuous production before manufacturing at commercial scale can drive value creation in a late-stage manufacturing process. Additionally, as we offer a short feasibility study, this is a low-risk method for evaluating the benefits our workflow can bring, without impeding development timelines.

Learn More

With high attrition rates of mAbs in early phase clinical trials, it is becoming increasingly challenging for biopharmaceutical companies to rapidly deliver high quality therapeutic mAbs using conventional antibody screening and fed-batch bioprocessing methods. This is why new Quality by Design (QbD) approaches such as using in silico AI and ML platforms to discover and optimize mAb sequences, high-throughput screening, and continuous intensified manufacturing processes such as those used at Just- Evotec Biologics are critical for enabling a paradigm shift in reducing attrition rates.

As detailed in this article, optimizing mAb design, using automated, miniaturized screening, and minimizing time in culture can deliver high-quality mAbs for FIH trials in rapid response times of around 12 months. In the future using this approach could expand access to life changing treatments, as well as support a rapid response to global health emergencies.

Learn More

By leveraging intensification, minimization, and simplification in bioprocessing workflows, Just-Evotec Biologics can achieve higher productivity, better resource utilization and lower facility costs. Collectively, these benefits contribute to reducing the COGM of biotherapeutics.

Continuous biomanufacturing arrives in Europe:

Nick Hutchinson, Head of Market Development at Just – Evotec Biologics, explains the benefits of this new approach, why the company’s new cGMP manufacturing facility, J.POD® Toulouse, France (EU), is the first of its kind in Europe and what this means for the industry.

Learn More